Song Eun-Ji, Shin Na Rae, Jeon Songhee, Nam Young-Do, Kim Hojun
Research Group of Personalized Diet, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, South Korea.
Department of Rehabilitation Medicine of Korean Medicine, Dongguk University, Goyang-si, Gyeonggi-do, South Korea.
Front Pharmacol. 2022 Nov 15;13:1042833. doi: 10.3389/fphar.2022.1042833. eCollection 2022.
Obesity is a chronic metabolic disease caused by excessive body fat and has become a global public health problem. Evidence suggests that obesity and obesity-induced metabolic disorders are closely related to gut microbiota. Bupropion (BP), an antidepressant medicine, and Stapf [Ephedraceae; Ephedrae Herba], a herbal medicine, are sympathetic stimulants and have weight loss effects. However, to our best knowledge, no studies have simultaneously assessed the effects of drugs and herbal medicines on obesity and gut microbiota. This study aimed to determine the effects of BP and ES on weight loss and re-modulation of host gut microbiota. To test this hypothesis, we fed C57BL/6J mice with a high-fat diet supplemented with bupropion (BP; 30 mg/kg/day) and Stapf extract (ES; 150 mg/kg/day) oral gavage for eight weeks. Further, we evaluated the effects of BP and ES on body weight and fat accumulation. In addition, we evaluated the effects of BP and ES on gut microbiota using 16S rRNA amplicon sequencing. Our results showed that weight loss was confirmed in both BP and ES; however, it was more pronounced in ES. ES changed the overall composition of the gut microbiota by restoring the relative abundance of , , and the / ratio, an indicator of gut microbiota dysbiosis. Nine amplicon sequence variants (ASVs) of the gut microbiome were significantly recovered by BP and ES treatment, of which eight ASVs correlated with body weight and fat accumulation. Additionally, three ASVs were significantly recovered by ES treatment alone. In conclusion, the anti-obesity effects of BP and ES, especially fat accumulation, are related to the regulation of gut microbiota. Moreover, ES had a greater influence on the gut microbiota than BP.
肥胖是一种由体内脂肪过多引起的慢性代谢性疾病，已成为全球公共卫生问题。有证据表明，肥胖及肥胖引起的代谢紊乱与肠道微生物群密切相关。安非他酮（BP）是一种抗抑郁药，麻黄（麻黄科；麻黄草）是一种草药，二者均为交感神经兴奋剂，具有减肥作用。然而，据我们所知，尚无研究同时评估药物和草药对肥胖及肠道微生物群的影响。本研究旨在确定BP和麻黄提取物（ES）对体重减轻及宿主肠道微生物群重新调节的影响。为验证这一假设，我们给C57BL/6J小鼠喂食高脂饮食，并通过口服灌胃给予安非他酮（30毫克/千克/天）和麻黄提取物（150毫克/千克/天），持续八周。此外，我们评估了BP和ES对体重及脂肪堆积的影响。另外，我们使用16S rRNA扩增子测序评估了BP和ES对肠道微生物群的影响。我们的结果表明，BP组和ES组均出现体重减轻；然而，ES组更为明显。ES通过恢复某些菌属的相对丰度以及肠道微生物群失调指标的菌属比例/比值，改变了肠道微生物群的整体组成。BP和ES处理显著恢复了肠道微生物组的9个扩增子序列变体（ASV），其中8个ASV与体重和脂肪堆积相关。此外，单独ES处理显著恢复了3个ASV。总之，BP和ES的抗肥胖作用，尤其是对脂肪堆积的作用，与肠道微生物群的调节有关。此外，ES对肠道微生物群的影响比BP更大。
